Positive Trending Data from 57 Per-Protocol Patients Suggest NE3107 is Biologically Active and May Have Impact on Cognitive, Functional, and Biomarker.
29.11.2023 - Positive Trending Data from 57 Per-Protocol Patients Suggest NE3107 is Biologically Active and May Have Impact on Cognitive, Functional, and Biomarker Endpoints Sponsor Identified Issues Relating to Significant GCP Violations and Protocol .
BioVie Inc. (BIVI) reported positive analysis of unblinded, topline efficacy data from Phase 3 clinical trial of NE3107 in the treatment of mild to moderate Alzheimer's Disease.
BioVie blames trial sites for phase 3 Alzheimer's drug fail fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
BioVie Inc (NASDAQ:BIVI) said that blinded data presented at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston suggests its drug.